- Press Contact
- VP Operations & Site Manager Sweden
- Operations & Uppsala Site Responsibilty
- +46 (0)18 751 35 00
As previously reported, Akademikliniken in Stockholm are conducting a clinical evaluation of TIGR® Matrix Surgical Mesh, the world’s first long-term resorbable synthetic surgical mesh, designed and manufactured by Novus Scientific in Uppsala, Sweden. As the collaboration so far has been successful, the parties have agreed to extend the scope of the collaboration.
Dynamic Reconstruction, the evolution of TIGR® Matrix is defined through three resonating points:
· 100% synthetic resorbable matrix, which is consistent over 3 years
· Excellent tissue integration, via macro-porosity
· Strength and flexibility, allowing native tissue remodeling under tension by moving in unison with the dynamic contours of the human body
Most notable and innovative are the latter points of improved tissue integration and the flexibility in a synthetic matrix never before possible. Dynamic Reconstruction, the evolution of TIGR® Matrix transcends the limitations of earlier biologics and synthetics by offering the highest caliber of patient care, firmly establishing Novus Scientific as the leader in soft tissue reinforcement.
Novus Scientific, the emerging pioneer in the creation of Dynamic Reconstruction – the evolution of TIGR® Matrix, is the trend provocateur in soft tissue reinforcement in plastic aesthetic and reconstructive surgery. TIGR® Matrix emerges as an undisputed alternative to devices that are more expensive, biologic or permanent in nature. As such, the value and credibility of TIGR® Matrix is on the rise worldwide.
TIGR® Matrix Surgical Mesh is a degradable surgical matrix made from synthetic resorbable polymers intended to support and reinforce tissue for 6-9 months and absorb completely after 3 years. The product is used for tissue reinforcement in general- and plastic surgery. TIGR® Matrix is CE marked (2011) and has been cleared for marketing by the US FDA (2010).
Novus Scientific was founded in 2008 by the Swedish entrepreneur Thomas Engström following the sale of Radi Medical Systems to the American St. JudeMedical, Inc. Over 20 years, Radi Medical Systems built up a leading position in the world of interventional cardiology. Today, Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable (100% absorbable) synthetic medical devices. Global HQ and core R&D functions are based in Uppsala, Sweden. The US Division is headquartered in San Diego and the Asian sales office resides in Singapore.
Contact Novus Scientific: firstname.lastname@example.org
About Novus Scientific
Novus Scientific was founded in 2008 by the Swedish entrepreneur Thomas Engström following the sale of Radi Medical Systems to the American St. Jude Medical, Inc. Over 20 years, Radi Medical Systems built up a leading position in the world of interventional cardiology. Today, Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable (100% absorbable) synthetic medical devices. Global HQ and core R&D functions are based in Uppsala, Sweden. The US Division is headquartered in San Diego and the Asian sales office resides in Singapore.
TIGR® is a registered trademark of Novus Scientific Pte. Ltd
Dr Hilton Becker Dr Jeffrey Lind have investigated the outcomes of using TIGR® Matrix in reconstructive, revision and cosmetic breast surgery in 62 patients. There results were recently published in Aesthetic Plastic Surgery. The full-text article is available through open access at Springer: http://link.springer.com/article/10.1007/s00266-013-0171-8
Jeffrey G. Lind II and Hilton Becker present a case study on the use of the TIG R® Matrix for bilateral breast augmentation revision for a patient with asymmetry, synmastia, and unnatural implant movement
Pioneers in resorbable devices for soft tissue reinforcement, Novus Scientific, will showcase the revolutionary TIGR® Matrix at ‘Beauty through Science’ (BTS) hosted by Akademikliniken in Stockholm from May 29th-31st.
Patients will be evaluated for recurrences and pain after one and three years. A total of 268 patients will be included at five different sites in Europe.
Dr Frederik Berrevoet at the University Hospital of Ghent, Belgium is the principal coordinating investigator of the study. “We are eager to start including patients in this very important study. If we can show that the clinical results are superior when using an absorbable mesh, then this can fundamentally change the way we approach surgery to repair ventral hernias and restore the integrity of the abdominal wall”.
Ventral or incisional hernias occur as a result of a weakness of the abdominal wall, often due to a prior surgical incision. They are surgically repaired through the introduction of a reinforcing mesh, which traditionally is a permanent mesh that remains in the patient for the rest of his/her life – with the increased risk of long-term complications such as chronic pain.
“We are convinced that a permanent prosthesis is not always necessary when treating what should be a temporary problem”, says Henrik Hjort, Product Manager of TIGR® Matrix at Novus Scientific. “The absorption and mechanical characteristics of TIGR® Matrix will likely lead to a better quality of life for the patients after their surgery. That some of the world’s most prominent researchers in this field are going to study this in a structured and scientific manner is very exciting”.
About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable (100% absorbable) synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company’s roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is based in San Diego, CA.
TIGR® Matrix (www.tigrmatrix.com) - The world’s 1st long-term resorbable, 100% absorbable synthetic mesh with unique patented dual-fiber construction, designed for gradually increasing mechanical compliance.
TIGR® is a registered trademark of Novus Scientific Pte. Ltd
The study is a double-blinded multicenter randomized controlled trial where a long-term absorbable mesh, TIGR® Matrix, will be evaluated for use in surgical repair of primary and secondary ventral hernias. The control group will receive a standard light-weight polypropylene mesh.
Akademikliniken (Stockholm), one of the world’s leading private plastic surgery clinics and Novus Scientific, developer of TIGR® Matrix, the world’s first long-term absorbable surgical matrix for reinforcement of soft tissue (used globally in abdominal wall surgery and in breast reconstructions after cancer operations) collaborate on the evaluation of TIGR® Matrix in aesthetic breast surgery.
Uppsala Cancer Clinic, specialists in peritoneal cancer treatment and gynecological tumor surgery, select TIGR® Matrix from Novus Scientific as a tool to further improve the quality of life for patients undergoing peritoneal cancer surgery. In order to avoid early complications the abdominal wall is now being reinforced using TIGR® Matrix, a synthetic long-term absorbable mesh.
Singapore / Novus Scientific, manufacturer of TIGR® Matrix Surgical Mesh (TIGR® Matrix), the world’s first long-term resorbable (100% absorbable) synthetic mesh, announces the submission of early results (1 year) TRAM flap data gathered by the Division of Plastic Reconstructive & Aesthetic Surgery at NUH Singapore at the 3rd World Congress for Plastic Surgeons of Chinese Descent in Xi'an, China.
Novus Scientific is the subject of an article in this quarters edition of Handelskammartidningen STHLM (the Journal of the Stockholm Chamber of Commerce), written by Victoria Lagercrantz. The text is reproduced in English (translation Novus Scientific).
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Our Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The US Division, Novus Scientific, Inc. is headquartered in San Diego.
E-mail has been sent